Comar's 18-mm SecureCap child-resistant closure for eye drops and nasal sprays meets US Consumer Product Safety Commission for products containing 0.08 milligrams or more of imidazolines.
Comar's 18-mm SecureCap child-resistant closure for eye drops and nasal sprays meets US Consumer Product Safety Commission (CPSC) for products containing 0.08 milligrams or more of imidazolines. The closure uses a patented, two-piece, push-and-turn technology that is effective for child resistance and is senior-friendly. Comar introduced a 15-mm SecureCap in 2014.
The CPSC regulations requiring special packaging for over the counter and prescription products containing 0.08 milligrams or more of a specified imidazoline (tetrahydrozoline, naphazoline, oxymetazoline, or xylometazoline) in a single package were to come into effect Dec. 10, 2013. Because companies were unable to meet this deadline, the CPSC extended the deadline to Dec. 10, 2014, and again to June 10, 2015. "It was apparent from the public comments that some of the companies would have to incorporate child-resistant closures in aseptic filling lines, which could cause delays. We’re prepared to help,” said Michael Ruggieri, CEO of Comar, in a press release. Comar's can be used with existing materials to minimize a manufacturer’s need for stability testing, and closures can be applied using existing capping equipment on most filling lines. Comar's technical staff are prepared to work with manufacturers and packagers to assist them in complying with CPSC regulations.